Systemic enhancement of antitumour immunity by peritumourally implanted immunomodulatory macroporous scaffolds

Nat Biomed Eng. 2023 Jan;7(1):56-71. doi: 10.1038/s41551-022-00977-0. Epub 2022 Dec 22.

Abstract

A tumour microenvironment abundant in regulatory T (Treg) cells aids solid tumours to evade clearance by effector T cells. Systemic strategies to suppress Treg cells or to augment immunity can elicit autoimmune side effects, cytokine storms and other toxicities. Here we report the design, fabrication and therapeutic performance of a biodegradable macroporous scaffold, implanted peritumourally, that releases a small-molecule inhibitor of transforming growth factor β to suppress Treg cells, chemokines to attract effector T cells and antibodies to stimulate them. In two mouse models of aggressive tumours, the implant boosted the recruitment and activation of effector T cells into the tumour and depleted it of Treg cells, which resulted in an 'immunological abscopal effect' on distant metastases and in the establishment of long-term memory that impeded tumour recurrence. We also show that the scaffold can be used to deliver tumour-antigen-specific T cells into the tumour. Peritumourally implanted immunomodulatory scaffolds may represent a general strategy to enhance T-cell immunity and avoid the toxicities of systemic therapies.

MeSH terms

  • Animals
  • Antigens, Neoplasm / metabolism
  • Disease Models, Animal
  • Immunity
  • Mice
  • Neoplasms* / therapy
  • T-Lymphocytes, Regulatory*
  • Tumor Microenvironment

Substances

  • Antigens, Neoplasm